Skip to main content
Fig. 2 | Genome Biology

Fig. 2

From: A novel long noncoding RNA HOXC-AS3 mediates tumorigenesis of gastric cancer by binding to YBX1

Fig. 2

Identification of HOXC-AS3 and expression of HOXC-AS3 in GC tissues and its clinical parameters and gain of H3K4me3 and H3K27 acetylation could activate HOXC-AS3 in GC. a HOXC-AS3 expression in GC tissues (n = 285) compared with noncancerous tissues (n = 33) analyzed using the TCGA database (data from TANRIC). b The full sequence of HOXC-AS3 was confirmed by RACE. c HOXC-AS3 was detected in 112 pairs of GC tissues by qRT-PCR. The levels of HOXC-AS3 in GC tissues are significantly higher than in nontumor tissues. The ΔCt value was determined by subtracting the GAPDH Ct value from the HOXC-AS3 Ct value. A smaller ΔCt value indicates higher expression. d HOXC-AS3 expression was significantly higher in patients with an advanced TNM stage. e Patients with high levels of HOXC-AS3 expression showed reduced survival times compared with patients with low levels of HOXC-AS3 expression (P < 0.01, log-rank test). f Kaplan–Meier survival plots demonstrating that high HOXC-AS3 expression levels correlated with worse OS in GC patients (n = 631). g The UCSC Genome Bioinformatics Site (http://genome.ucsc.edu/) showed high enrichment of H3K4me3 and H3K27Ac at the promoter of HOXC-AS3. ChIP assays detected the level of H3K4me3 and H3K27Ac at the promoter of HOXC-AS3 in GC tissues and cells. *P < 0.05, **P < 0.01

Back to article page